Neuronal Protein Tracing Reveals How the Brain Routes Its Waste

The brain is one of the busiest organs in the body, constantly processing and reshaping itself. That activity produces an equally constant stream of molecular byproducts—proteins that need to be moved out before they accumulate. When those clearance routes slow or break down, waste lingers, and the consequences can be profound. In Alzheimer’s disease, for example, toxic proteins build up in vulnerable regions. Yet despite decades of research, scientists have lacked a clear view of how waste normally leaves the brain.

A new study from the Gladstone Institutes offers the clearest picture yet of how the brain normally takes out its trash—and what happens when those routes fail. Published in Cell as “Physiological brain clearance architecture revealed by neuronal protein tracing,” the work introduces a method that traces waste proteins from the moment they are produced inside neurons to the moment they leave the brain.

For decades, researchers have relied on injecting tracers into the cerebrospinal fluid (CSF) to visualize drainage. But this approach, while illuminating, shows all possible routes, instead of pinpointing the most-used exit. “These injected tracers disturb the very system we’re attempting to measure,” said lead author Andrew Yang, PhD, a Gladstone investigator. “We wanted to find a better way.”

Yang’s team engineered neurons in mice to produce a fluorescent protein, ZsGreen, that could be followed as it exited the brain through its natural routes. This allowed the researchers to track waste as it moved into the dura, skull, nasal cavity, and lymph nodes—regions populated by specialized immune cells that interact with brain‑derived proteins.

The resulting map diverged sharply from the field’s long‑held assumptions. Traditional CSF tracers had pointed to the cervical lymph nodes as a major drainage site. But the new method revealed that very little neuronal waste actually reaches those nodes. “We were surprised to find that very little ZsGreen drained to the cervical lymph nodes,” Yang said. “Instead, waste drained through the dura, skull, and nasal cavity. Our findings underscore why tracking waste proteins themselves, rather than movement of the cerebrospinal fluid, provides a more accurate understanding of waste clearance dynamics.”

The team also uncovered a striking organizational principle: where a protein is made determines where it drains. Proteins produced in upper forebrain regions exited through upper routes, while those from deeper structures, such as the striatum, used lower pathways. The researchers call this the brain’s “nearest‑exit” model. “It’s like each brain region has a biological ZIP code system to ensure waste will be sent to the correct drainage site,” said Nalini Rao, PhD, a postdoctoral fellow. She noted that in aging or disease, these ZIP codes may become scrambled, potentially explaining why certain regions are more vulnerable to disorders like Alzheimer’s.

Disease models reinforced the system’s fragility. In mice with acute inflammation, ZsGreen leaked directly into the bloodstream, bypassing normal routes. In an Alzheimer’s model, waste became trapped inside the brain, unable to drain effectively. “Understanding how diseases disrupt brain clearance could help us design therapeutics to target the brain border compartments and enhance waste removal,” Rao said.

With their new tracing method, Yang’s group plans to probe how clearance changes across aging, sleep, and disease—and whether brain tumors exploit these pathways to evade immune detection. The architecture of brain waste disposal, once opaque, is now open for exploration.

The post Neuronal Protein Tracing Reveals How the Brain Routes Its Waste appeared first on GEN – Genetic Engineering and Biotechnology News.

STAT+: Allogene CEO David Chang stepping down

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hiya. In this week’s episode of “The Readout LOUD,” biotech vet Jeremy Levin talks about how scientific progress is outpacing the institutions that support it. Also, WHO experts are recommending the use of an antiviral and two monoclonal antibodies in the response to the Bundibugyo Ebola outbreak, and Allogene CEO David Chang is stepping down.

The need-to-know this morning

  • Replimune Group said it had reached an agreement with the FDA to resubmit its experimental melanoma drug for approval, after the therapy was twice rejected by the agency.

Albert Bourla loves China 

We are referring, of course, to the Pfizer CEO, who is once again putting billions of dollars of Pfizer cash on the table to buy drugs invented in China. 

Continue to STAT+ to read the full story…

The Download: unlocking lithium and controlling Ebola

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

How a new extraction process could unlock the world’s lithium

A new method for extracting lithium could cut costs and emissions from one of the world’s most important materials for EVs and energy storage. 

The technique uses a weak acid to dissolve silicate minerals. That frees not only the lithium but also other useful materials, including alumina and silica. 

“At scale, we believe this will be the lowest-cost way of sourcing lithium in the world,” says Yet-Ming Chiang, an MIT professor who co-authored a study of the process published yesterday in Science. 

Startup Rock Zero is already working to commercialize the research. Read the full story on a new way to unlock the world’s lithium.

—Casey Crownhart

The deadly Ebola outbreak is proving difficult to control

The alert was raised on May 5. Four health-care workers in the Democratic Republic of the Congo had died from an unknown illness within four days. Tests in Kinshasa revealed the culprit: the Bundibugyo virus, one of the causes of Ebola.

A couple of weeks ago, an outbreak of hantavirus erupted aboard a cruise ship. Three people died, but the outbreak was kept under control. The picture for Ebola is bleaker for several reasons, including the disease itself, the available treatments, and the local environment.

Find out why the outbreak is causing alarm.

—Jessica Hamzelou

This story is from The Spark, our weekly newsletter giving you the inside track on all things biotech. Sign up to receive it in your inbox every Thursday.

How the Pope’s Magnifica Humanitas offers a template for individuals to meet the AI moment

——Father Séamus Finn, a leader in faith-based and socially responsible investing with the Oblates of Mary Immaculate, and Sister Susan Francois, assistant congregation leader and treasurer of the Sisters of St. Joseph of Peace

Pope Leo XIV’s new encyclical on artificial intelligence includes a statement that warrants serious attention from technologists and policymakers: “Technology is never neutral.” 

Magnifica Humanitas is a call to act with courage and solidarity as AI transforms human life, framing the choice ahead as one between the Tower of Babel and the rebuilding of our common humanity. It warns that corporations alone cannot set the direction of such a transformation.

With governments slow to regulate AI, institutional investors are stepping into the gap. Here’s how they can build a better future.

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Anthropic is now valued higher than OpenAI
It hit a $965 billion valuation after a new funding round. (AP News)
+ Claude demand has driven annualized revenue to $47 billion. (WSJ $)
+ The funding round may be Anthropic’s last before an IPO. (TechCrunch)
+ What even is the AI bubble? (MIT Technology Review)

2 A Blue Origin rocket has exploded in a setback to NASA’s Moon plans
New Glenn burst into flames during testing on a Florida launchpad. (CNBC)
 + Blue Origin is heavily involved in NASA’s Moon base plans. (The Verge)
 + It also wants to compete with Elon Musk’s SpaceX. (Reuters $)
 
3 Adversaries are tracking US troop locations via mobile phone data
The Pentagon has long ignored warnings of this exact threat. (Reuters $)
+ The targeting uses commercially available location data. (Wired $)
+ LLMs could supercharge mass surveillance. (MIT Technology Review)
 
4 Anthropic plans a broad rollout of Mythos AI in the coming weeks
Despite concerns over its cybersecurity capabilities. (CNET)
+ Claude Opus 4.8 is now out, with a promise to be more honest. (The Verge)
 
5 Grok oversaw a crime spree in an AI safety test
Models were tasked with governing a simulated society. (Fortune)
+ Grok committed 180 crimes, while Claude ruled with restraint. (Gizmodo)

6 Amazon has scrapped an AI leaderboard after worker gaming
Employees were artificially inflating usage scores. (FT $)
+ We can build better AI benchmarks. (MIT Technology Review)
 
7 Political spending by AI and crypto groups is shifting elections
They’ve pushed their preferred candidates closer to power. (Axios)

8 China’s tech boom is fueling a new wave of industrial tourism
Visitors are touring AI labs and EV factories. (Rest of World)

9 Alibaba’s MuleRun aims to replicate the OpenClaw craze
The AI agent platform is positioned as a safer alternative. (SCMP)

10 Mysterious changes have emerged in the Sun’s magnetic field
They could reshape space weather forecasts. (404 Media)

Quote of the day

“What Peter Thiel is doing is terrible. His settling in Argentina is even worse.”


—Elisa Lilita Carrió, an Argentine politician, writes on X that Peter Thiel’s relocation to her country has angered her even more than his leadership of Palantir.

One More Thing

NASA, ESA, CSA, STSCI, WEBB ERO PRODUCTION TEAM


How the James Webb Space Telescope broke the universe

When the James Webb Space Telescope began full operations in 2022, astronomers were in awe of the flood of data that arrived.

“Every hour we were looking at a galaxy or an exoplanet or star formation,” says NASA scientist Heidi Hammel. “It was like a firehose.”

Since then, JWST has delivered nonstop discoveries, from distant galaxies to new planetary atmospheres. “We’re cracking open an entirely new window on the universe,” says Hammel. 

Discover how JWST has transformed astronomy.

—Jonathan O’Callaghan

We can still have nice things

A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)

+ Kubrick fans will love this Lego recreation of Dr Strangelove.
+ Here’s a fascinating explanation of why seven landlocked countries have navies.
+ This mesmerizing 4K remaster of a super typhoon turns weather data into cinematic art.
+ Go inside the genius of Queen with this track-by-track breakdown of “Bohemian Rhapsody.”

Bonito Biosciences and DaltonTx Collaborate on Precision Delivery for Oligotherapeutics

Bonito Biosciences and DaltonTx agreed to collaborate to help advance next-generation precision delivery systems for Bonito’s oligotherapeutic medicines. The collaboration will initially focus on delivery to the central nervous system, combining Bonito’s functional delivery data engine and ligand discovery platform with DaltonTx’s AI systems which are designed to iteratively model, predict, and optimize precision delivery biology.

Together, the companies will work to identify, optimize, and advance delivery ligands for conjugated oligotherapeutic payloads, including novel bispecific approaches for targeted CNS delivery, according to officials at both firms.

Through its functional selection platform, Bonito screens hundreds of billions of encoded ligands against complex cellular delivery phenotypes, explained a Bonito spokesperson, adding that these datasets–physically generated and directly tested on cell systems of interest– capture high-dimensional information related to receptor engagement and cellular delivery.

DaltonTx will apply its AI capabilities to model these data and to work on accelerating the design and optimization of next-generation delivery ligands through structural prediction, affinity mapping, and developability analysis. Together, the companies aim to establish an iterative learning loop for the rapid discovery of precision delivery systems for conjugated oligotherapeutics, noted Richard Wagner, CEO of Bonito.

“This collaboration brings together two highly complementary capabilities: Bonito’s ability to generate uniquely rich functional delivery data at massive scale and DaltonTx’s deep expertise in adaptive AI systems for molecular design and optimization,” he continued. “We believe precision delivery is fundamentally a data and prediction problem. By combining closed-loop functional screening with AI-driven design, we aim to accelerate the discovery of delivery systems capable of reaching tissues and cell types that have historically remained inaccessible to oligotherapeutics.”

“AI systems are only as powerful as the quality and dimensionality of the underlying biological data,” pointed out Garry Pairaudeau, CEO and co-founder of DaltonTx. “Bonito has built a uniquely differentiated platform for generating functional delivery datasets at extraordinary scale. Combining these data with DaltonTx’s agentic AI platform, which integrates AI, human expertise, and experimental data into one continuous learning engine, has the potential to significantly accelerate the discovery of next-generation delivery systems for conjugated oligotherapeutics.”

 

 

The post Bonito Biosciences and DaltonTx Collaborate on Precision Delivery for Oligotherapeutics appeared first on GEN – Genetic Engineering and Biotechnology News.

The deadly Ebola outbreak is proving difficult to control

The alert was raised on May 5. Four health-care workers in the Ituri Province of the Democratic Republic of the Congo had died from an unknown illness within four days.

Rapid response teams were sent to investigate, and tests at a research center in Kinshasa revealed the culprit: the Bundibugyo virus, one of the viruses that cause Ebola. Suspected cases of the disease have snowballed in the last few weeks. By May 24, the WHO had estimated that 223 people had died from the disease. There were over 900 suspected cases. Today’s figures are likely to be higher.

A couple of weeks ago, I covered the hantavirus outbreak aboard a cruise ship. Three people sadly died, but the outbreak itself was kept under control. There have been no further deaths, and passengers have been safely repatriated. The picture for Ebola is far bleaker. And there are several reasons why.

The most obvious is the disease itself. Ebola is a severe disease with an average 50% fatality rate. Previous outbreaks have resulted in thousands of deaths. (Hantavirus also has a high fatality rate, but it doesn’t usually spread as easily between humans.) 

Between 2014 and 2016, an Ebola outbreak in West Africa caused more than 11,000 deaths. A more recent outbreak, which took place between 2018 and 2020, caused 2,299 deaths before being brought under control with a vaccination campaign.

But those outbreaks were caused by the Zaire virus, which has a different genetic sequence. There is no vaccine for the Bundibugyo virus. We don’t know if the two vaccines approved for Zaire might also work for Bundibugyo. There’s a concern they might even make things worse by interfering with a person’s immune response to the virus.  

Scientists are working on potential Bundibugyo vaccines. But the most advanced efforts are still months away from clinical trials. There are no specific antiviral treatments for the virus, either.

So to control the outbreak, health-care workers are trying to stop the spread of the disease. Ebolaviruses can be transmitted to humans by animals including fruit bats, chimpanzees, and gorillas. They can then spread between people via contact with bodily fluids such as blood or vomit.

That’s why the virus is often spread among family members, to health-care workers, and during some burial services. The WHO advises isolating people who have the virus in treatment centers. It also recommends safe burial measures that limit physical contact with the deceased, for example. Communities need to be informed about the virus and how it spreads, and health professionals should be on hand to diagnose cases and track them.

That’s all easier said than done in an era of misinformation. Some members of the community even doubt whether the disease is real. There have been three attacks on health-care facilities in the region in recent weeks.

Last week, two treatment centers were burned down. The first incident occurred after relatives of a deceased man were prohibited from retrieving his (infectious) body. As a result of the second incident, 18 suspected cases reentered the community.

A couple of days later, a group of men unleashed gunfire at Mongbwalu General Hospital, which was also treating people with Ebola. They were demanding the bodies of their deceased relatives.

There are more causes for concern when it comes to the spread of the virus. The Ebola outbreak is thought to have originated in Mongbwalu, a high-traffic mining hub. People who caught the virus in Mongbwalu are thought to have sought care in neighboring districts. And the wider province borders both South Sudan and Uganda. So far, Uganda has reported seven confirmed cases and one death. South Sudan’s health ministry has said it will strengthen surveillance, but no cases have been reported in the country so far. 

Violence in the region is making it much harder to contain the spread of the virus, too. Conflict involving multiple armed groups, including deadly attacks on civilians, has hampered humanitarian and health-care efforts. Poor infrastructure and damaged roads make matters even worse. Food insecurity is ravaging the region as well—this year, nearly 10 million people in the region face acute hunger.

Together, these factors are making it “nearly impossible” to isolate people with Ebola and trace others who have been in contact with them, WHO director general Tedros Adhanom Ghebreyesus said in a statement earlier this week.

The dismantling of US aid programs hasn’t helped either. US government funding for international health projects has steeply declined since the start of President Donald Trump’s second term. These cuts have harmed disease surveillance systems, according to the International Rescue Committee, a humanitarian nonprofit.

“Funding cuts have left the region dangerously exposed,” Heather Reoch Kerr, the organization’s country director for the Democratic Republic of the Congo, said in a statement. “Years of underinvestment and recent funding cuts have left many health facilities without adequate protective equipment, surveillance capacity, or frontline support needed to respond quickly and safely.”

The US has mobilized emergency funding for the outbreak, and a spokesperson for the State Department has argued that none of the administration’s actions have hampered the Ebola response. But health experts counter that the damage has already been done.

On May 17, the WHO declared the Ebola outbreak a public health emergency of international concern. In a statement on Wednesday, Tedros described the situation as “a catastrophic collision of disease and conflict with the Ebola outbreak in Ituri province outpacing the response.”In an online appeal to residents on Wednesday, ahead of an in-person visit, Tedros pleaded for a ceasefire and commended the spirit of community members. He also acknowledged the steep challenges they face. “You are already carrying so much: malaria, hunger, insecurity, and the daily struggle to keep your families safe,” he wrote in French. “And now Ebola. It’s not fair, and I won’t pretend otherwise.”

This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

MTD Micro Molding appoints Chad Nikel as CEO

NEWS RELEASE: MTD Micro Molding appoints Chad Nikel as chief executive officer Former MedTech CDMO CEO and Haemonetics executive brings specialized medical device CDMO leadership to MTD’s next phase of growth in precision micro manufacturing. CHARLTON, MA — MTD Micro Molding has appointed Chad Nikel as Chief Executive Officer, effective May 11, 2026. Nikel brings extensive…

The post MTD Micro Molding appoints Chad Nikel as CEO appeared first on Medical Design and Outsourcing.

STAT+: Biotech veteran Jeremy Levin on why the industry’s future is secure, but American leadership is at risk

Biotech is producing scientific breakthroughs that once seemed impossible. But according to longtime industry executive Jeremy Levin, the institutions that support these advances, from regulators, to investors, and even public trust in science itself — are beginning to fracture.

Levin is the founder and chairman of Ovid Therapeutics and former CEO of Teva Pharmaceuticals. In his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust,” he argues that political upheaval, weakening institutions, short-term investing, and more are putting the future of the industry at risk, even though the science itself continues to accelerate.

On this week’s episode of “The Readout Loud,” Levin advocates for federal changes that could incentivize biotech investment, and for pharmaceutical companies, in particular, to call out how regulatory upheaval is harming the drug industry. “When an institution such as this, which is critical, is shaken, the industry must stand firm. It must call out why this is a problem. … The titans are dead silent right now,” he said. 

Below are highlights from his conversation with hosts Elaine Chen, Adam Feuerstein, and Allison DeAngelis.

This transcript of the interview has been lightly edited for length and clarity.

Continue to STAT+ to read the full story…

Biotech exec Jeremy Levin on the industry’s strategic turning point

On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” That sounds alarmist, and it is in some respects, but as Levin explains, the book is also a roadmap to a brighter future for the biotech industry.

But first, we recap the week’s biotech news, including an Eli Lilly gene-editing treatment for high cholesterol, a new round of funding for a longevity startup, and a preview of the upcoming ASCO cancer research meeting. 

Read the rest…

Targeting Metabolic Mechanism Restores Chemotherapy Sensitivity in Ovarian Cancer

Although many cancers can be successfully treated using platinum-based chemotherapies, which work by damaging DNA, a subset avoid cell death by repairing their own DNA. Ovarian cancers are an example. Patients whose tumors are DNA repair proficient historically face poor prognosis and their tumors commonly recur within months. 

Now data from a new study done in cells and mice points to a potential metabolic target that could prevent tumor cells from repairing their own DNA, thus overcoming their resistance. The work was done by scientists from The Wistar Institute, Temple University, and their collaborators elsewhere. Details are published in a new Nature paper titled “αKG-mediated carnitine synthesis drives DNA repair via histone acetylation.” In it, they describe a metabolic process that is altered in cancer cells that makes them resistant to DNA-damaging agents. They have also identified a drug that can inhibit the pathway that may offer a strategy for overcoming chemotherapy resistance. 

Specifically, the study centers on alpha-ketoglutarate (αKG), a metabolite which accumulates in DNA repair proficient ovarian tumors. First, the scientists confirmed αKG’s role in helping ovarian cancer cells repair DNA and survive chemotherapy treatment. They did this by using a CRISPR-based approach to systematically search for the enzyme that enables αKG to repair DNA. 

Previous studies on αKG focused on its role in demethylation of proteins and other molecules. Though the scientific literature pointed towards demethylases as the key enzyme, the scientists focused onTMLHE, an enzyme that initiates the synthesis of carnitine, a molecule often associated with energy metabolism. “Finding TMLHE was the moment I thought, ‘Okay, this is going to be something bigger than what we expected,’” said Katherine Aird, PhD, professor and co-leader of the molecular and cellular oncogenesis program at The Wistar Institute and senior author of the study.

The data indicated that elevated αKG activates TMLHE, which drives carnitine production. Carnitine then carries acetyl groups out of the mitochondria and into the nucleus where they are deposited onto histones. This loosens the DNA-histone complex which allows the cells repair machinery to access and fix DNA damage. 

Next the team showed that when TMLHE or carnitine synthesis is blocked, histone acetylation does not occur which prevents the DNA repair machinery from doing its work. In these cases, the cells become significantly more sensitive to DNA-damaging chemotherapies. “The connection between αKG and methylation is well established—that’s what everyone studies,” said Nathaniel Snyder, PhD, associate professor in the Aging + Cardiovascular Discovery Center at Temple University School of Medicine. “What we found is that αKG is also controlling acetylation through a completely separate route, and that route turns out to be essential for DNA repair. That’s a new piece of biology that nobody had described before.”

As part of the study, the scientists tested the effects of mildronate, a carnitine synthesis inhibitor, and cisplatin, a platinum-based DNA-damaging chemotherapy drug. They found that the combination of these treatments reduced the tumor burden in mouse models of ovarian cancer, while neither drug alone produced a significant effect. Additionally, patients with high TMLHE expression in tumor tissue had significantly worse progression-free survival post chemotherapy, and higher serum acetylcarnitine levels at diagnosis correlated with faster disease progression. 

That latter finding suggests that it may one day be possible to use a routine blood test for circulating acetylcarnitine to identify patients that are most likely to resist standard platinum-based cancer treatments, and to benefit from a combination therapy. 

The post Targeting Metabolic Mechanism Restores Chemotherapy Sensitivity in Ovarian Cancer appeared first on GEN – Genetic Engineering and Biotechnology News.

How a new extraction process could unlock the world’s lithium

Researchers say they’ve found a new way to extract lithium, a crucial metal used in the lithium-ion batteries that power electric vehicles and energy storage arrays. This new technique could be more environmentally friendly and cheaper than existing ones. 

The research was published today in Science, and a startup called Rock Zero is working to commercialize the process.

“At scale, we believe this will be the lowest-cost way of sourcing lithium in the world,” says Yet-Ming Chiang, one of the study authors, who is an MIT professor and a serial entrepreneur behind climate tech companies including Form Energy and Addis Energy.

The most economical way to get lithium currently is to extract it from brine, salty water that’s pulled the metal out of rock over the course of millennia. But this technique is geographically limited and currently requires vast tracts of land for massive evaporation pools. The more common tactic is hard-rock mining, where large bodies of ore are blasted apart, cooked at high temperatures, and processed using dangerous chemicals.

The researchers’ new method uses a weak acid to dissolve typically nonreactive silicate minerals. That frees not only the lithium but also other useful materials, including alumina and silica.

The origin story for this research, and the resulting company, came from another startup founded by Chiang, Sublime Systems, which makes cement using electrochemistry.

The team was trying to find a source of highly reactive silica in order to form stronger cement. One way to make reactive materials, which can bond easily with other materials, is to take a nonreactive material, dissolve it, and then allow it to become solid in a more reactive form. It’s not impossible to dissolve silicates, but the best-known way is to use hydrofluoric acid, an extremely dangerous chemical. Other fluorine-containing chemicals are candidates too, but some will produce hydrofluoric acid as a side product during reactions. 

Chiang drew inspiration from a previous home renovation project involving glass, which is made of silica. “I was remodeling a shower in Framingham, Massachusetts, about 25 years ago,” he says. “So when we started this project, I remembered that glass etching cream and thought, ‘What’s in that?’” 

The glass etching cream he remembered, which can be found on shelves at any craft or home improvement store, uses ammonium fluoride, a weak acid. And the MIT researchers discovered that in the right conditions, it can effectively dissolve silicate minerals without producing hydrofluoric acid in the process.

This chemistry could be useful for any silicate minerals—and there are a lot of them. But spodumene, the mineral that’s often mined for lithium, became a prime first target. (Chiang says a suggestion from Doug Wicks, one of the company’s advisors and a former ARPA-E official, pointed the team in spodumene’s direction.)

small pieces of rock next to a line of 3 capped vials of powder
From left to right: spodumene, silica, alumina and lithium salts.
ROCK ZERO

Today, a key step in processing spodumene ore is to roast it in a kiln at super-high temperatures. This causes a phase transformation, essentially puffing up the material and making the lithium more accessible.

By avoiding the need to reach these temperatures, you could save on energy costs and potentially reduce carbon emissions as well, says Camden Hunt, one of the authors of the study and the CEO and cofounder of Rock Zero.

Avoiding the kiln could also unlock the ability to use some ores that can’t be roasted properly, Hunt adds. Ore that contains too much iron won’t go through the phase change correctly, instead melting and turning into a glassy material.

The new process relies on simple stirred plastic tanks and takes place at temperatures up to about 95 °C (200 °F). The ammonium fluoride dissolves the silicates, which in earlier experiments allowed nearly all of the lithium inside the spodumene ore to be extracted within a couple of days. The researchers have since cut this time to under 12 hours, says Benjamin Mowbray, first author of the study and the CTO and cofounder of Rock Zero.  

The products (after some additional steps to clean them up) are lithium carbonate, which can be used to make batteries; alumina, which can go into a smelter to make aluminum; and cementitious silica, which can be added into concrete. And the acid can be reused in the same loop.

Chiang calls this “nose-to-tail” mining—using every part of the ore provided, like eating every part of a butchered animal.

The researchers are currently working to scale and optimize the process. The tanks in the lab in Cambridge, Massachusetts can handle three kilograms of spodumene concentrate in each batch. 

They have also estimated the cost of this process once fully scaled up. Assuming that the ammonium fluoride can be recycled at a high level, they should be able to extract lithium for less than $6,000 per metric ton. (They’ve identified a potential cheap industrial source of the acid as well, as an alternative to recycling it.) 

The total cost is projected to be lower than that of other processes used to extract lithium from hard-rock ore today, and it could be competitive with brine.

The team has designed a pilot plant and is looking for space to build it. The plan is to have construction done by the end of 2026 and start operating the facility in 2027. Talks are underway with potential partners in the mining industry.

One difficulty for new players in lithium extraction is the volatility of the market: Prices have seen huge swings in recent years, from a peak in 2022 to lows in late 2024 and a slow climb starting in early 2026. 

Rising prices might benefit new players like Rock Zero, but there are many projects that could come online if prices continue to rise, and that could bring the market right back down, says Simon Jowitt, chair of exploration geology at the University of Nevada, Reno. “People are waiting to see what happens with the lithium price,” he says. “It’s a crowded market, and there’s some big players out there.”

And even though batteries are driving up demand for lithium, the market is still relatively small, Jowitt adds: “That means it’s going to be volatile.” New lithium extraction technologies like Rock Zero’s will have to compete with methods used by existing giants, and there’s also the potential that technological alternatives, like sodium-ion batteries that don’t need lithium, could make the market more difficult to navigate, Jowitt says. He also thinks some of the company’s economic estimates could be optimistic.

For its part, Rock Zero’s team hopes not only to scale this technology for lithium, but to use it for other minerals in the future. As Mowbray says, “The Earth’s crust is made of silicates.”